Press Releases Kintara Therapeutics, Inc.

Equities

KTRA

US49720K2006

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
0.1311 ^USD	+2.42%		-11.78%	-22.70%

Apr. 03	Sector Update: Health Care Stocks Softer Late Afternoon	MT
Apr. 03	Sector Update: Health Care	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kintara Therapeutics : Shareholder Meeting - Form 8-K	May. 09	PU
TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	Apr. 26	AQ
Kintara Therapeutics : TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - Form 8-K	Apr. 25	PU
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRA	Apr. 09	PR
KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA	Apr. 05	BU
Shareholder Alert: Ademi LLP investigates whether Kintara Therapeutics, Inc. has obtained a Fair Price in its transaction with TuHURA	Apr. 03	PR
KTRA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Kintara Therapeutics, Inc. Is Fair to Shareholders	Apr. 03	BU
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab	Mar. 27	PR
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)	Feb. 21	AQ
Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update	Feb. 14	PR
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer	Feb. 12	PR
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)	Dec. 22	AQ
Basal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	Dec. 20	AQ
Kintara Therapeutics Announces Review of Strategic Alternatives	Dec. 07	PR
Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders Equity Continued Listing Requirement	Dec. 06	AQ
Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement	Dec. 05	PR
Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update	Nov. 13	PR
Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study	23-10-31	PR
Kintara Therapeutics to Present at the 8th Annual Dawson James Small Cap Growth Conference	23-10-11	PR
Kintara Therapeutics to Present at the LD Micro Main Event XVI Conference	23-10-02	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Kintara Therapeutics, Inc.

Equities

KTRA

US49720K2006

Press Releases

Filters